 Scleroderma, Systemic
"Scleroderma, Systemic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
| Descriptor ID |
D012595
|
| MeSH Number(s) |
C17.300.799 C17.800.784
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Scleroderma, Systemic".
Below are MeSH descriptors whose meaning is more specific than "Scleroderma, Systemic".
This graph shows the total number of publications written about "Scleroderma, Systemic" by people in this website by year, and whether "Scleroderma, Systemic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 | | 1995 | 0 | 1 | 1 | | 1997 | 1 | 0 | 1 | | 1998 | 1 | 0 | 1 | | 2000 | 2 | 0 | 2 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 2 | 2 | | 2003 | 1 | 0 | 1 | | 2004 | 1 | 0 | 1 | | 2006 | 1 | 0 | 1 | | 2007 | 5 | 0 | 5 | | 2008 | 2 | 0 | 2 | | 2009 | 3 | 2 | 5 | | 2010 | 4 | 0 | 4 | | 2011 | 1 | 0 | 1 | | 2012 | 2 | 1 | 3 | | 2013 | 3 | 0 | 3 | | 2014 | 2 | 1 | 3 | | 2015 | 1 | 0 | 1 | | 2016 | 2 | 1 | 3 | | 2017 | 3 | 0 | 3 | | 2019 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Scleroderma, Systemic" by people in Profiles.
-
Li SC, Fuhlbrigge RC, Laxer RM, Pope E, Ibarra MF, Stewart K, Mason T, Becker ML, Hong S, Dedeoglu F, Torok KS, Rabinovich CE, Ferguson PJ, Punaro M, Feldman BM, Andrews T, Higgins GC. Developing comparative effectiveness studies for a rare, understudied pediatric disease: lessons learned from the CARRA juvenile localized scleroderma consensus treatment plan pilot study. Pediatr Rheumatol Online J. 2019 Jul 15; 17(1):43.
-
Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med. 2019 06 27; 380(26):2518-2528.
-
Cottin V, Brown KK. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir Res. 2019 Jan 18; 20(1):13.
-
Fischer A, Strek ME, Cottin V, Dellaripa PF, Bernstein EJ, Brown KK, Danoff SK, Distler O, Hirani N, Jones KD, Khanna D, Lee JS, Lynch DA, Maher TM, Millar AB, Raghu G, Silver RM, Steen VD, Volkmann ER, Mullan RH, O'Dwyer DN, Donnelly SC. Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities. Arthritis Rheumatol. 2019 02; 71(2):182-195.
-
Fischer A, Kong AM, Swigris JJ, Cole AL, Raimundo K. All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement. J Rheumatol. 2018 02; 45(2):235-241.
-
Fischer A, Zimovetz E, Ling C, Esser D, Schoof N. Humanistic and cost burden of systemic sclerosis: A review of the literature. Autoimmun Rev. 2017 Nov; 16(11):1147-1154.
-
Fischer A, Donnelly SC. Pulmonary fibrosis in connective tissue disease (CTD): urgent challenges and opportunities. QJM. 2017 08 01; 110(8):475-476.
-
Distler O, Brown KK, Distler JHW, Assassi S, Maher TM, Cottin V, Varga J, Coeck C, Gahlemann M, Sauter W, Schmidt H, Highland KB. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™). Clin Exp Rheumatol. 2017 Sep-Oct; 35 Suppl 106(4):75-81.
-
Morisset J, Vittinghoff E, Elicker BM, Hu X, Le S, Ryu JH, Jones KD, Haemel A, Golden JA, Boin F, Ley B, Wolters PJ, King TE, Collard HR, Lee JS. Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model. Chest. 2017 11; 152(5):999-1007.
-
Calderone A, Stevens W, Prior D, Nandurkar H, Gabbay E, Proudman SM, Williams T, Celermajer D, Sahhar J, Wong PK, Thakkar V, Dwyer N, Wrobel J, Chin W, Liew D, Staples M, Buchbinder R, Nikpour M. Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol. BMJ Open. 2016 12 08; 6(12):e011028.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|